RESUMO
The illegal use of clenbuterol in feeding of cattle has caused outbreaks of food poisoning in humans that consume beef and internal organs. Since 2007, with the modification of the Ley Federal de Sanidad Animal, the use of clenbuterol as growth promoter is penalized and coordinated actions are announced between the Secretaria de Salud (SSA) and the Secretaria de Agricultura, Ganaderia, Desarrollo Rural, Pesca y Alimentacion (Sagarpa) on concurrent issues. This study analyzed the implementation of the procedures in the public health sector, as well as the coordinated activities between SSA and Sagarpa in Queretaro and Jalisco states in Mexico. Results indicate that a higher degree of collaboration between these two institutions is required in the exchange of information from Sagarpa to SSA derived from penal procedures, as well as in the identification of improvement action procedures, thus optimizing the results achieved by both institutions in concurring actions related to sanitary surveillance of clenbuterol use.
El uso ilegal del clenbuterol en la alimentación de los bovinos ha ocasionado la presentación de brotes de intoxicación a partir del consumo de carne y vísceras. A partir de la modificación en 2007 de la Ley Federal de Sanidad Animal, el uso de esta sustancia como promotora del crecimiento está tipificado como delito y a su vez, se anuncian acciones coordinadas entre la Secretaría de Salud (SSA) y la Secretaría de Agricultura, Ganadería, Desarrollo Rural, Pesca y Alimentación (Sagarpa) en asuntos concurrentes. En el presente estudio se analizaron las actividades de la SSA en concurrencia con la Sagarpa de tipo intersectorial, para la vigilancia sanitaria, tomando como estudio de caso las entidades de Querétaro y Jalisco. Los resultados indicaron que se requiere mayor colaboración por parte de la Sagarpa hacia la SSA para notificar sus resultados derivados de los procedimientos penales, así como en la colaboración para la identificación de procesos de acciones de mejora, lo cual ayudará a optimizar las iniciativas de ambas autoridades en las acciones concurrentes de la vigilancia sanitaria en el uso del clenbuterol.
RESUMO
Control and eradication of zoonoses is a priority because there can only be human health if there is animal health, and both will not exist if the environment is not healthy. This concept is called "One Health" Mexico has demonstrated its capacity to eradicate various zoonoses such as Venezuelan equine encephalitis, yellow fever cattle screwworm, and highly pathogenic avian influenza. Zoonoses and emerging and reemerging diseases and food-borne diseases are called neglected diseases. They provoke disease and diminish food security. Their presence is seen in marginalized populations with lags in their development that reflect the lack of equity in our society; these diseases are the product of the lack of attention to the social determinants of health and risk factors. Tackling these diseases should be comprehensive, with intersectoral, interdisciplinary, and transdisciplinary approaches. Government agencies located in the human/animal health environment interface do not have established limits of liability and there are overlapping and empty spots; legislation is insufficient to guarantee collaboration. It is urgent to have reforms and new forms of organizations, regionalized according to the epidemiological situation; at the municipal level, a priority is to formalize an effective service of veterinary public health. New impetuses to address the persistent social and health lags are proposed.
Assuntos
Zoonoses/epidemiologia , Animais , México/epidemiologiaRESUMO
Se describen algunos aspectos de la biotecnología para la producción de anticuerpos monoclonales, y se analizan los usos de los mismos en el diagnóstico, en la prevención, y en el tratamiento de las enfermedades; además, se describen algunas condiciones que se consideran necesarias para la producción de anticuerpos monoclonales y la disponibilidad de los hibridomas comerciales, analizándose también los factores que limitan las posibilidades futuras para el empleo de los anticuerpos monoclonales